S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
Log in
NASDAQ:SRPT

Sarepta Therapeutics Stock Forecast, Price & News

$96.80
+6.48 (+7.17 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$91.20
Now: $96.80
$97.14
50-Day Range
$82.29
MA: $152.10
$178.74
52-Week Range
$78.06
Now: $96.80
$181.83
Volume3.40 million shs
Average Volume6.08 million shs
Market Capitalization$7.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics logo

MarketRank

Overall MarketRank

1.94 out of 5 stars

Analyst Opinion: 4.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRPT
Previous SymbolNASDAQ:AVII
CUSIPN/A
Phone617-274-4000
Employees743

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$380.83 million
Book Value$10.98 per share

Profitability

Net Income$-715,080,000.00
Net Margins-121.30%

Miscellaneous

Market Cap$7.64 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$96.80
+6.48 (+7.17 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

How has Sarepta Therapeutics' stock price been impacted by COVID-19?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SRPT shares have decreased by 5.9% and is now trading at $96.80.
View which stocks have been most impacted by COVID-19
.

Is Sarepta Therapeutics a buy right now?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Sarepta Therapeutics?

Wall Street analysts have given Sarepta Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sarepta Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Sarepta Therapeutics
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($2.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.89) by $0.61. The biotechnology company had revenue of $143.92 million for the quarter, compared to analyst estimates of $133.69 million. Sarepta Therapeutics had a negative return on equity of 61.62% and a negative net margin of 121.30%. Sarepta Therapeutics's revenue was up 45.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.14) earnings per share.
View Sarepta Therapeutics' earnings history
.

What price target have analysts set for SRPT?

24 brokers have issued 12 month price objectives for Sarepta Therapeutics' stock. Their forecasts range from $73.00 to $240.00. On average, they expect Sarepta Therapeutics' stock price to reach $161.96 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Sarepta Therapeutics' key competitors?

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and The Walt Disney (DIS).

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:
  • Mr. Douglas S. Ingram, Pres, CEO & Director (Age 57, Pay $1.39M)
  • Mr. William F. Ciambrone, Exec. VP of Technical Operations (Age 56, Pay $438.01k)
  • Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 48, Pay $731.8k)
  • Dr. Gilmore O'Neill M.D., Exec. VP of R&D and Chief Medical Officer (Age 55, Pay $933.33k)
  • Mr. Joseph Bratica, Controller, VP and Interim Principal Financial & Accounting Officer (Age 56)
  • Mr. Ian M. Estepan, Sr. VP of Corp. Affairs & Chief of Staff
  • Dr. Diane L. Berry, Sr. VP of Global Health Policy and Gov. & Patient Affairs
  • Ms. Joan Nickerson M.B.A., Sr. VP of HR
  • Dr. Louise Rodino-Klapac Ph.D., Sr. VP of Gene Therapy
  • Dr. Edward M. Kaye, Advisor (Age 71)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include DNB Asset Management AS (0.04%), IFM Investors Pty Ltd (0.01%), OneAscent Financial Services LLC (0.00%), BLB&B Advisors LLC (0.00%), XR Securities LLC (0.00%) and Redpoint Investment Management Pty Ltd (0.00%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics
.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, BLB&B Advisors LLC, XR Securities LLC, Redpoint Investment Management Pty Ltd, Vigilare Wealth Management, IFM Investors Pty Ltd, Exchange Traded Concepts LLC, and Patriot Financial Group Insurance Agency LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $96.80.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $7.64 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-715,080,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. Sarepta Therapeutics employs 743 workers across the globe.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is www.sareptatherapeutics.com.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.